Evidence-based·Last reviewed May 31, 2026·How we grade evidence

Agarikon

Botanical

Agarikon (Laricifomes officinalis, sometimes called Fomitopsis officinalis) is a slow-growing, old-growth conifer-dwelling polypore mushroom with a long tradition of use in Indigenous Pacific Northwest medicine and European 'quinine conk' folk practice. Modern interest comes from in-vitro reports of antiviral activity against pox-family viruses, herpes simplex, influenza, and TB. No human clinical trials exist. Wild populations are IUCN Vulnerable; only farmed sources should be used.

Quick decision guide

May help most

Adults curious about traditional functional mushrooms who understand that all current evidence is preclinical or anecdotal and want a low-dose adjunct alongside standard care.

Common dosing range

Most commercial products provide 500–1,000 mg dried fruiting body or 500 mg dual-extract per day. There is no clinically validated dose.

When to expect effects

Not established. Traditional users describe weeks of daily use as part of seasonal immune protocols.

Watch out for

All claims are preclinical or traditional. There is no human evidence that agarikon prevents or treats any infection, including the viruses where in-vitro activity has been reported. Don't substitute it for vaccination, antiviral medication, or evidence-based care.

Evidence snapshot

In-vitro antiviral activity (pox, herpes, flu, TB)Moderate (preclinical)

Human clinical evidence for any indicationAbsent

Traditional use (Pacific NW, Europe)Documented

Sustainability / wild harvestVulnerable species

What is it

Agarikon (Fomitopsis officinalis, formerly Laricifomes officinalis) is a long-lived bracket fungus from old-growth coniferous forests, used traditionally and in modern functional mushroom products.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You're interested in traditional functional mushrooms as a low-risk adjunct to evidence-based care

You're sourcing from a farmed (cultivated) supplier with third-party testing — wild agarikon populations are IUCN Vulnerable

You're approaching it as 'might help, won't hurt' rather than expecting clinical effects

Probably skip if…

You're hoping to replace antiviral medications or vaccines — no human evidence supports this and missed evidence-based treatment is the real risk

You're considering it for an active infection (COVID, flu, herpes, TB) — see a clinician for proper treatment

You're tempted by wild-harvested agarikon — the species is IUCN Vulnerable and old-growth populations cannot sustain commercial harvest

You're price-sensitive — concentrated dual-extract polypore products are expensive and the evidence-to-cost ratio is poor

You have a known mushroom or mold allergy — fungal-derived supplements can trigger reactions

Evidence at a glance

Goal	Effect	Best fit	Time
Antiviral activity (in-vitro / preclinical) Mixed Evidence	Cell-culture inhibition of pox, herpes, influenza, and mycobacterium at micromolar concentrations; no human data	Researchers and traditional-medicine practitioners interested in early-stage candidate antivirals	Not established
Anti-inflammatory / immunomodulatory traditional use Mixed Evidence	Not established in humans	People interested in traditional plant-medicine practice	Not established
Antitumor / cancer-related claims Mixed Evidence	Not established in humans	None — see oncology care for cancer treatment	Not established

Antiviral activity (in-vitro / preclinical)

Mixed Evidence

Effect: Cell-culture inhibition of pox, herpes, influenza, and mycobacterium at micromolar concentrations; no human data
Best fit: Researchers and traditional-medicine practitioners interested in early-stage candidate antivirals
Time: Not established

Anti-inflammatory / immunomodulatory traditional use

Mixed Evidence

Effect: Not established in humans
Best fit: People interested in traditional plant-medicine practice
Time: Not established

Antitumor / cancer-related claims

Mixed Evidence

Effect: Not established in humans
Best fit: None — see oncology care for cancer treatment
Time: Not established

Evidence for 3 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

Antiviral activity (in-vitro / preclinical)

Mechanism only

Mixed Evidence

In-vitro studies (Stamets 2003 Pacific Northwest screening; Girometta 2019 comprehensive review) report agarikon extracts inhibit replication of orthopoxviruses (vaccinia, related models), herpes simplex viruses 1 and 2, influenza A and B, and Mycobacterium tuberculosis at micromolar concentrations. The active classes are lanostane triterpenoids and chlorinated coumarins. None of these laboratory findings have been validated in human clinical trials, and there is no published evidence that oral agarikon supplements achieve antiviral concentrations in human serum.

Effect size

Cell-culture inhibition of pox, herpes, influenza, and mycobacterium at micromolar concentrations; no human data

Time to effect

Not established

Best fit

Researchers and traditional-medicine practitioners interested in early-stage candidate antivirals

Less likely

Anyone hoping for clinical antiviral protection or treatment — see a clinician for vaccines, antivirals, and TB therapy

Bottom line: Promising laboratory chemistry; zero clinical evidence. Don't substitute it for vaccines or prescribed antivirals.

SourceGirometta, 2019 — Mycology (Taylor & Francis)Stamets et al., 2003 (preprint/Fungi report) — International Journal of Medicinal Mushrooms / Fungi Perfecti

Anti-inflammatory / immunomodulatory traditional use

Mechanism only

Mixed Evidence

Indigenous Pacific Northwest peoples (Tlingit, Haida) used agarikon for chest infections, tuberculosis-like illness, and as a general 'good medicine.' European folk medicine used the 'quinine conk' for fevers, asthma, and as a bitter tonic. Modern in-vitro work shows triterpenoid effects on macrophages and cytokine signaling. No clinical evidence supports specific anti-inflammatory or immunomodulatory effects in humans.

Effect size

Not established in humans

Time to effect

Not established

Best fit

People interested in traditional plant-medicine practice

Less likely

Anyone with serious inflammatory disease — use evidence-based treatments

Bottom line: Traditional use is interesting context but doesn't substitute for clinical evidence.

SourceGirometta, 2019 — Mycology (Taylor & Francis)

Antitumor / cancer-related claims

Mechanism only

Mixed Evidence

Several mushroom polypores have demonstrated immunomodulatory and antitumor activity in cell-culture and animal models (mostly via beta-glucan polysaccharide pathways). Agarikon specifically has limited tumor-related research; the better-studied medicinal mushrooms for cancer adjunct use are Trametes versicolor (turkey tail) and Ganoderma lucidum (reishi). No human cancer trials of agarikon exist.

Effect size

Not established in humans

Time to effect

Not established

Best fit

None — see oncology care for cancer treatment

Less likely

Anyone substituting agarikon for evidence-based oncologic therapy

Bottom line: Use turkey tail or reishi (both have stronger evidence) if you want a polypore adjunct, and only with oncology team input.

SourceGirometta, 2019 — Mycology (Taylor & Francis)

How it works

Agarikon contains triterpenoids, polysaccharides (including beta-glucans), and antiviral compounds. In vitro screening has shown activity against influenza, pox, and herpes viruses, prompting research interest. Human clinical data are essentially absent. Like other medicinal mushrooms, beta-glucans in agarikon may modulate innate immunity by activating dectin-1 receptors on macrophages and neutrophils.

How to take it

1. Typical dose

• Dried fruiting body powder: 500–1,000 mg/day in capsules (typical commercial range) • Dual extract (hot water + alcohol): 500 mg/day equivalent • Tincture: per manufacturer directions (typically 1–2 mL, 1–2× daily) • There is no clinically validated effective dose

2. Higher studied dose

There are no human dose-finding studies. Anecdotal traditional 'high-dose' use is in the 2–4 g/day range; this is not safety-validated.

3. Timing

Any time. Some traditional protocols recommend morning use; some manufacturers suggest with food to reduce GI upset.

4. With food

With food to reduce mild GI discomfort that's common with concentrated polypore extracts.

5. Split dosing

Split daily dose into 2 servings (morning + afternoon) if using >500 mg/day.

6. How long to try

Traditional 'seasonal' protocols use 4–12 weeks during cold/flu season. There is no clinical guidance on safe maximum duration; reassess every 8–12 weeks.

What to track

Subjective immune response, frequency of upper respiratory infections (but accept that confounders dominate)

GI tolerance — mild bloating or loose stools at higher doses

Any rash or allergic symptoms

Source: confirm cultivated, not wild-harvested (IUCN Vulnerable species)

Bottom line: Treat agarikon as an experimental traditional adjunct, not a clinical-grade intervention. Use cultivated sources, don't expect demonstrated antiviral effects, and don't replace standard care.

5 commercial forms

Compare the main delivery options and what they’re best suited for.

Dried fruiting body capsules / powder

Traditional

Ground dried sporocarp from cultivated agarikon. Closest to the traditional preparation. Look for fruiting-body sourcing (not mycelium-on-grain).

Polysaccharides and triterpenoids both present; oral absorption of triterpenoids is variable.

Dual extract (hot water + alcohol)

Modern

Concentrated extract designed to capture both water-soluble polysaccharides and alcohol-soluble triterpenoids. The most likely to deliver the in-vitro active compound classes.

Concentrated; expensive; still no human PK data.

Tincture (alcohol-extracted)

Liquid

Alcohol-extracted concentrate. Traditional liquid form. Variable strength by manufacturer; absorption favored for sublingual use.

Sublingual route may improve bioavailability of triterpenoids over swallowed capsules.

Mycelium-on-grain product

Cheaper but weaker

Mycelium grown on a grain substrate and dried with the grain — labeled simply as 'agarikon mycelium.' Per-gram triterpenoid content is much lower than fruiting body. Prefer fruiting-body products if budget allows.

Much of the product mass is grain starch; effective dose per capsule is lower.

Wild-harvested raw conks

Avoid

Wild Fomitopsis/Laricifomes officinalis from old-growth conifer forests. IUCN Vulnerable; commercial harvest is unsustainable and often regulated. Cultivated alternatives exist — choose those.

Ethically and ecologically problematic; do not purchase wild-harvested product.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

mild GI upset (bloating, loose stools) at higher dosesbitter tasterare allergic reactions in mushroom-sensitive people

Serious risks

No serious risks have been characterized in modern clinical data, but there is also no formal safety database — concentrated polypore extracts have not been studied at length in pregnant women, children, or people with chronic disease.
SourceGirometta, 2019 — Mycology (Taylor & Francis)
Allergic reactions including respiratory and skin symptoms can occur in people with mushroom or mold sensitivities.
SourceGirometta, 2019 — Mycology (Taylor & Francis)
Sustainability concern (not a health risk per se): Laricifomes officinalis is IUCN Vulnerable; buying wild-harvested products contributes to species decline. Choose cultivated sources only.
SourceIUCN Red List — Laricifomes officinalis — International Union for Conservation of Nature

Who should avoid it

Pregnant or breastfeeding women — no safety data; concentrated polypore extracts haven't been studied in pregnancy.
SourceGirometta, 2019 — Mycology (Taylor & Francis)
People with mushroom or mold allergies.
SourceGirometta, 2019 — Mycology (Taylor & Francis)
Immunocompromised people (post-transplant, advanced HIV, active chemotherapy) — fungal-derived supplements may carry contamination risk and immunomodulatory effects are unstudied.
SourceGirometta, 2019 — Mycology (Taylor & Francis)
Children — no pediatric data.
SourceGirometta, 2019 — Mycology (Taylor & Francis)

Pregnancy & breastfeeding

Avoid in pregnancy and breastfeeding — no clinical or formal toxicology data exist for human pregnancy. Concentrated polypore extracts have unknown effects on fetal development. Use better-studied alternatives (e.g., a balanced diet, vitamin D, prenatal vitamin) for immune support during pregnancy.

SourceGirometta, 2019 — Mycology (Taylor & Francis)

Bottom line: Generally well-tolerated in healthy adults at typical doses, but with thin safety data. Skip during pregnancy, in mushroom allergy, or in immunosuppression. Source cultivated, not wild.

Interactions

immunosuppressants (tacrolimus, cyclosporine, biologics)Moderate

Polypore mushroom extracts have in-vitro immunomodulatory activity that could theoretically reduce immunosuppressant efficacy. Clinical magnitude unknown.

SourceGirometta, 2019 — Mycology (Taylor & Francis)

anticoagulants (warfarin, DOACs)Minor

Some polypore preparations contain mild antiplatelet compounds. No clinical interaction data for agarikon specifically; monitor INR/clinical signs if combining.

diabetes medicationsMinor

Animal data suggest mild blood-glucose effects with some polypore extracts. Monitor glucose if combining with insulin or sulfonylureas.

other antivirals and antibioticsMinor

No documented clinical interaction. Don't substitute agarikon for prescribed antivirals or antibiotics for any infection.

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

Cultivated source (sustainable, not wild-harvested) — Fomitopsis officinalis is IUCN Vulnerable

Whole fruiting body vs mycelium — fruiting body has more characterized triterpenoid content; mycelium-grown-on-grain products may contain mostly grain starch (look for 'fruiting body' on label)

Dual extraction (hot water + alcohol) for both polysaccharide and triterpenoid extraction

Third-party tested for heavy metals, microbial contamination, and species verification (DNA-tested if available)

Standardized to beta-glucan content or 'polysaccharide content ≥X%' — provides at least a chemical marker

Country of origin and harvest method disclosed

Be skeptical of…

'Antiviral' or 'antibiotic' claims — only in-vitro data exist; no human evidence

'Cures TB / herpes / flu / pox' — none of these have human clinical support

'Wild old-growth-forest sourced' as a marketing premium — encourages depletion of an IUCN Vulnerable species

'Cancer treatment' or 'tumor-shrinking' — no clinical data; use better-studied alternatives only as oncology adjuncts

Mega-dose 'extract concentrates' priced as miracle cures — evidence-to-cost ratio is poor

Combination 'immune boost stacks' with proprietary blends that don't disclose individual mushroom amounts

Frequently asked questions

Does agarikon fight COVID or flu?⌄

There is no human clinical evidence supporting use against any specific viral infection. Lab data are preliminary.

References by claim

Antiviral activity (in-vitro / preclinical)

Girometta, 2019 — Mycology (Taylor & Francis) (2019) link

Stamets et al., 2003 (preprint/Fungi report) — International Journal of Medicinal Mushrooms / Fungi Perfecti (2003) link

Safety

IUCN Red List — Laricifomes officinalis — International Union for Conservation of Nature (2019) link

Other references

Liu et al., 2018 — Journal of Natural Medicines (2018) link

Laricifomes officinalis on Wikidata — Wikidata link

Agarikon on NIH DSLD — NIH Dietary Supplement Label Database link

Track Agarikon with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store

Evidence-based·Last reviewed May 31, 2026·Evidence current as of May 31, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.